NCT00977158

Brief Summary

The goal of this study is characterize the changes in bacterial diversity of the upper respiratory tracts of infants with cystic fibrosis (CF). Another goal is to determine when CF patients become colonized with pathogenic bacteria that are responsible for the lethal lung damage in children with CF. Ten subjects will be recruited into the study. Throat swabs will be collected at 6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age in order to chart any changes in the bacterial populations of the respiratory tract. Clinical data will also be collected to evaluate the possible influence of external factors on changes in the microbial communities. This study will provide preliminary data on whether probiotics can eradicate the colonization of the respiratory tract by pathogenic bacteria.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

2 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 14, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 15, 2009

Completed
1.6 years until next milestone

Study Start

First participant enrolled

May 1, 2011

Completed
Last Updated

March 18, 2015

Status Verified

March 1, 2015

First QC Date

September 14, 2009

Last Update Submit

March 17, 2015

Conditions

Keywords

Cystic FibrosisMicrobiotaupper respiratory tract16S rRNA sequence analysisStaphylococcus aureusPseudomonas aeruginosaBurkholderia cepaciaHaemophilus influenzaeStreptococcus pneumoniae

Outcome Measures

Primary Outcomes (3)

  • To characterize the microbial ecology and changes in bacterial diversity of the oropharynx in a cohort of children with CF during the first year of life using 16S rRNA sequence analysis

    6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age

  • To describe the clinical variables that may be associated with changes in microbial ecology in children with cystic fibrosis over the first year of life

    6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age

  • To explore changes in the microbial ecology of the oropharynx in conjunction with Staphylococcus aureus colonization in children with CF

    6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age

Study Arms (1)

Throat Swab

Infants who have been diagnosed with cystic fibrosis

Procedure: Throat Swab

Interventions

Throat SwabPROCEDURE

Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.

Throat Swab

Eligibility Criteria

Age1 Day - 3 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Infants with cystic fibrosis

You may qualify if:

  • Male and female subjects, newborn to age 3 months
  • Have a diagnosis of cystic fibrosis (Diagnosis of CF will be based on either a positive sweat chloride of \>60 mEq/L or the identification of two detectable mutations associated with CF
  • Parent/guardian plans to have follow-up care for approximately one year at designated CF clinic
  • Parent/guardian provides informed consent to participate in the study

You may not qualify if:

  • Contraindications for obtaining oropharyngeal swabs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Floating Hospital for Children at Tufts Medical Center

Boston, Massachusetts, 02111, United States

Location

Children's Hospital Boston

Boston, Massachusetts, 02115, United States

Location

MeSH Terms

Conditions

Cystic FibrosisStaphylococcal InfectionsPseudomonas InfectionsHaemophilus Infections

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, DiseasesGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsGram-Negative Bacterial InfectionsPasteurellaceae Infections

Study Officials

  • Patricia L Hibberd, MD, PhD

    Tufts Medical Center

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 14, 2009

First Posted

September 15, 2009

Study Start

May 1, 2011

Last Updated

March 18, 2015

Record last verified: 2015-03

Locations